NFKBIA antibody (Ser32, Ser36)

Catalog No. ABIN197304

Product Details anti-NFKBIA Antibody

Target: NFKBIA (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, alpha (NFKBIA))

Binding Specificity: Ser32, Ser36

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This NFKBIA antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Specificity: IkappaB-alpha antibody detects endogenous levels of total IkappaB-alpha protein.

Purification: Immunoaffinity chromatography

Immunogen: Synthetic non-phosphopeptide derived from human IkappaB-alpha around the phosphorylation site of serine 32/36 (H-D-Sp-G-L-D-Sp-M-K).

Application Details

Application Notes: Suitable for use in Western blot (1: 500-1: 1000) and Immunohistochemistry (1: 50-1: 100).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % Sodium Azide and 50 % Glycerol.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: Store the antibody (in aliquots) at -20 °C.

References for anti-NFKBIA antibody (ABIN197304)

Tsolou, Liousia, Kalamida, Pouliliou, Giatromanolaki, Koukourakis: "Inhibition of IKK-NFκB pathway sensitizes lung cancer cell lines to radiation." in: Cancer biology & medicine, Vol. 14, Issue 3, pp. 293-301, (2017) (PubMed).

Target Details for NFKBIA

Target: NFKBIA (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, alpha (NFKBIA))

Alternative Name: NFKBIA / IKBA (NFKBIA Products)

Synonyms: IKBA antibody, MAD-3 antibody, NFKBI antibody, AI462015 antibody, Nfkbi antibody, RL/IF-1 antibody, ECI-6/IKBA antibody, NFKBIA antibody, ikbaB antibody, wu:fb81f08 antibody, zgc:56666 antibody, zgc:77616 antibody, ikbaA antibody, wu:fj16a07 antibody, zgc:85769 antibody, NFKB inhibitor alpha antibody, nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha antibody, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha b antibody, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha a antibody, NFKBIA antibody, Nfkbia antibody, nfkbiab antibody, nfkbiaa antibody

Background: Three major forms of IKB like molecules have been identified and each is characterised by multiple copies of ankyrin repeats. IkappaB alpha and IkappaB beta appear to be the major regulatory forms of IKB in most cells. These proteins interact with p65 or cRel containing forms of NFkappaB and block nuclear import by masking the nuclear localisation sequences of NFkappaB. The activation of NFkappaB involves the inducible phosphorylation and subsequent degradation of IkappaB. Immunoblotting easily detects the hyperphosphorylated forms of IkappaB alpha, but not phosphorylated IkappaB beta. Interestingly, IkappaB alpha and IkappaB beta mediate different NFkappaB responses. IkappaB alpha appears to control more transient activation of NFkappaB in response to an inducer, while IkappaB beta controls a persistent response. Bcl3 interacts with p50 and p52 containing forms of NFkappaB, but rather than being an inhibitor it appears to function to stimulate transcription. The degradation of IkappaB is confirmed by immunoblotting.Synonyms: I kappa B-alpha, I-kappa-B-alpha, IkB-alpha, IkappaBalpha, MAD3, Major histocompatibility complex enhancer-binding protein MAD3, NF-kappa-B inhibitor alpha, NFKBI

Gene ID: 4792

NCBI Accession: NP_065390

UniProt: P25963

Pathways: NF-kappaB Signaling, TCR Signaling, TLR Signaling, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Maintenance of Protein Location, Hepatitis C, Protein targeting to Nucleus, Toll-Like Receptors Cascades, BCR Signaling